• English
    • Deutsch
View Item 
  •   OPARU Home
  • Medizinische Fakultät
  • Publikationen
  • View Item
  •   OPARU Home
  • Medizinische Fakultät
  • Publikationen
  • View Item
  • English 
    • English
    • Deutsch
  • Login
JavaScript is disabled for your browser. Some features of this site may not work without it.

Effekte der Histondeacetylasehemmer Butyrat und Tributyrin beim humanen Prostatakarzinom in vitro und in vivo

Thumbnail
Download
vts_8881_13283.pdf (12.14Mb)
91 S.
 
Veröffentlichung
2014-01-30
DOI
10.18725/OPARU-3062
Dissertation


Authors
Altug, Vedat
Faculties
Medizinische Fakultät
License
Standard
https://oparu.uni-ulm.de/xmlui/license_v3
Abstract
Histone deacetylase inhibitors (HDACi) are a relatively new and promising class of drugs in the therapy of malignant diseases. They could demonstrate antiproliferative and proapoptoic effects on various tumours and cause changes in gene ecpression patterns in treated cells. In this thesis the in vitro and in vivo efficiency of the classic HDACi butyrate and its prodrug tributyrin on prostate cancer cells LNCaP and PC-3 were investigated. Methods: In vitro cell culture experiments were performed with focus on changes in cell morphology, proliferation and apoptosis. For in vivo testing tumour cells were seeded on chicken egg chorionallantois membrane (CAM) to analyze apoptosis rate and implanted in a xenograft model using nude mice for assesment of tumour growth and Ki-67 index. To gain more insight into the underlying pathways western blot analysis was performed for gene products p21, Rb, c-myc, bcl-2 and bcl-XL. Results: Both sodium butyrate and tributyrin had a considerable treatment effect on prostate cancer cells in vitro as well as in vivo causing morphologic changes in tumour cells, inhibiting proliferation, and increasing apoptosis rate in vitro and in vivo, leading to significantly smaller tumours in the mouse model, and decreasing Ki-67 index of mouse tumours. While in the mouse model there couldn"t be seen any significant differences in the potency of butyrate and tributyrin, in the other experiments tributyrin generally had a stronger effect than butyrate. Western-blot analysis showed an upregulation of p21, hypophosphorylation of Rb, downregulation of c-myc and bcl-XL while no changes where seen in bcl-2. A pathway model was suggested to explain the mode of action of HDACi. The given results are encouraging for performing clinical trials with butyrate/tributyrin as well as other HDACi as drugs for prostate cancer treatment or chemoprophylaxis, possibly in combination with or in addition to established treatment methods.
Date created
2014
Subject Headings
Apoptosis [GND]
Prostatakrebs [GND]
Butyrates [MeSH]
Histone deacetylase inhibitors [MeSH]
Prostatic neoplasms [MeSH]
Tributyrin [MeSH]
Dewey Decimal Group
DDC 610 / Medicine & health

Metadata
Show full item record

Citation example

Altug, Vedat (2014): Effekte der Histondeacetylasehemmer Butyrat und Tributyrin beim humanen Prostatakarzinom in vitro und in vivo. Open Access Repositorium der Universität Ulm. Dissertation. http://dx.doi.org/10.18725/OPARU-3062

Other citation formats



About OPARU | Contact Us
Impressum | Privacy statement
 

 

Advanced Search

Browse

All of OPARUCommunities & CollectionsFacultiesInstitutionsPersonsResource typesUlm SerialsDewey Decimal ClassesFundingThis CollectionFacultiesInstitutionsPersonsResource typesUlm SerialsDewey Decimal ClassesFunding

My Account

LoginRegister

Statistics

View Usage Statistics

About OPARU | Contact Us
Impressum | Privacy statement